Sichuan Biokin Stock Soars 7.41%, Hits Intraday High of CNY 340.00

Sichuan Biokin Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.41% on July 20, 2026. The stock reached an intraday high of CNY 340.00, marking a notable achievement for the company within the pharmaceuticals and biotechnology sector. Over the past week, Sichuan Biokin has outperformed the China Shanghai Composite, with a weekly gain of 12.22% compared to the index's decline of 3.0%. The company's one-month performance is particularly striking, showing a 46.54% increase against the backdrop of a 7.19% drop in the broader market. Despite these short-term gains, the company has faced challenges, reporting negative results for the last four consecutive quarters. Key financial metrics reveal a net sales figure of CNY 2,065.9 million, reflecting a decline of 63.52%, and a net profit of CNY -500.37 million, down 112.34%. The operating cash flow has also reached a low of CNY -2,331.46 million, indicating financial strain. Sichuan Biokin's market capitalization stands at CNY 21,049 million, positioning it as a large-cap player in its industry.